BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Saturday, May 10, 2025
Home » Authors » Aaron Lorenzo

Aaron Lorenzo

Articles

ARTICLES

Esperion's Public Offering Raises $64M For Pipeline

Aug. 4, 2003
By Aaron Lorenzo

Esperion's Public Offering Raises $64M For Pipeline

Aug. 4, 2003
By Aaron Lorenzo

Aventis Commits At Least $62M To ImmunoGen In Cancer Deal

Aug. 1, 2003
By Aaron Lorenzo
ImmunoGen Inc. received a commitment worth at least $62 million from Aventis SA, which in turn acquired a large share of ImmunoGen's pipeline as part of an agreement to jointly develop antibody-based cancer products. And the deal could get sweeter from there. (BioWorld Today)
Read More

Aventis Commits At Least $62M To ImmunoGen In Cancer Deal

Aug. 1, 2003
By Aaron Lorenzo
ImmunoGen Inc. received a commitment worth at least $62 million from Aventis SA, which in turn acquired a large share of ImmunoGen's pipeline as part of an agreement to jointly develop antibody-based cancer products. And the deal could get sweeter from there. (BioWorld Today)
Read More

Corautus Gets Lift From Boston Scientific Deal Worth Up To $25M

Aug. 1, 2003
By Don Long and Aaron Lorenzo

ILEX Raises $93.5M In Secondary Public Offering Of Common Stock

July 31, 2003
By Aaron Lorenzo
ILEX Oncology Inc. gained gross proceeds of $93.5 million through the sale of 5.5 million common shares priced at $17 apiece. (BioWorld Today)
Read More

ILEX Raises $93.5M In Secondary Public Offering Of Common Stock

July 31, 2003
By Aaron Lorenzo
ILEX Oncology Inc. gained gross proceeds of $93.5 million through the sale of 5.5 million common shares priced at $17 apiece. (BioWorld Today)
Read More

Private Sale Nets Sonus $13.1M For Cancer Drug Development

July 30, 2003
By Aaron Lorenzo
Sonus Pharmaceuticals Inc. more than doubled its cash holdings after raising net proceeds of about $13.1 million through the private placement of 3.9 million common shares to new and current institutional investors. (BioWorld Today)
Read More

Private Sale Nets Sonus $13.1M For Cancer Drug Development

July 30, 2003
By Aaron Lorenzo
Sonus Pharmaceuticals Inc. more than doubled its cash holdings after raising net proceeds of about $13.1 million through the private placement of 3.9 million common shares to new and current institutional investors. (BioWorld Today)
Read More

MGI Offering Could Gross $128M Following FDA Approval Of Aloxi

July 29, 2003
By Aaron Lorenzo
Capitalizing on a stock surge prompted by Friday's approval of a partnered cancer drug, MGI Pharma Inc. on Monday reported plans to sell 4 million shares. (BioWorld Today)
Read More
View All Articles by Aaron Lorenzo

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for May 9, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for May 9, 2025.
  • US flag, stock market chart, White House

    100 days of uncertainty

    BioWorld
    The first 100 days of the Trump administration have been nothing short of chaotic, both in the U.S. and throughout the world. Shining a light through the...
  • AI generated, 3D rendering of protein degradation

    AACR 2025: Induced proximity strategy, beyond degraders

    BioWorld
    Targeted protein degradation has yet to notch its first approval. But with more than two dozen agents now in clinical trials, the strategy’s ultimate clinical...
  • NME Digest: Q1 2025

    BioWorld
    A quarterly dynamic table featuring new molecular entities (NMEs) revealed for the first time in current literature, at congresses and in company communications...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing